Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy

2.1 Nivolumab (Opdivo, Bristol-Myers Squibb) has a marketing authorisation in the UK for 'the treatment of locally advanced or metastatic non‑small‑cell lung cancer after prior chemotherapy in adults'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price of nivolumab is £2,633 per 240 mg per 24‑ml vial (excluding VAT; BNF online, accessed March 2020). The company has a commercial arrangement. This makes nivolumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.